Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | XDH | P47989 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30509819 | 1.00 | EGFR (0.39) | EGFRERBB2DYRK1AGAAPTPN1 | |
| SCHEMBL6389982 | 0.86 | SSTR2 (0.39) | EGFRERBB2DYRK1AGAANPC1 | |
| SCHEMBL29122661 | 0.83 | DYRK1A (0.38) | EGFRERBB2DYRK1AGAANPC1 | |
| SCHEMBL6389985 | 0.82 | SMN1; SMN2 (0.32) | DYRK1ANPC1RAB9AALDH1A1HPGD | |
| SCHEMBL5846257 | 0.82 | PTPN1 (0.42) | EGFRPTPN1NPC1RAB9AMAPT | |
| SCHEMBL23269915 | 0.81 | PTPN1 (0.49) | EGFRERBB2GAAPTPN1XDH | |
| SCHEMBL30976506 | 0.80 | POLB (0.41) | EGFRERBB2DYRK1AGAATSHR | |
| SCHEMBL1423571 | 0.80 | POLB (0.41) | EGFRERBB2DYRK1AGAATSHR | |
| SCHEMBL28289636 | 0.80 | AR (0.39) | EGFRERBB2GAAPTPN1XDH | |
| SCHEMBL21884012 | 0.79 | TSHR (0.38) | EGFRERBB2GAAPTPN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240376067-A1 | PROCESS OF MAKING SOMATOSTATIN MODULATORS | Crinetics Pharmaceuticals, Inc. | 2024-11-14 | — | — | US | disclosed |
| CN-111868049-B | Process for preparing somatostatin modulators | 克林提克斯医药股份有限公司 | 2023-06-30 | — | — | CN | disclosed |
| EP-4092018-A1 | PROCESS OF MAKING SOMATOSTATIN MODULATORS | Crinetics Pharmaceuticals, Inc. (US) | 2022-11-23 | — | — | EP | disclosed |
| EP-3740475-B1 | PROCESS OF MAKING SOMATOSTATIN MODULATORS | CRINETICS PHARMACEUTICALS INC (US) | 2022-04-20 | — | — | EP | disclosed |
| US-20210087165-A1 | PROCESS OF MAKING SOMATOSTATIN MODULATORS | Crinetics Pharmaceuticals, Inc. | 2021-03-25 | — | — | US | disclosed |
| US-10889561-B2 | Process of making somatostatin modulators | Crinetics Pharmaceuticals, Inc. (US) | 2021-01-12 | — | — | US | disclosed |
| EP-3740475-A1 | PROCESS OF MAKING SOMATOSTATIN MODULATORS | Crinetics Pharmaceuticals, Inc. (US) | 2020-11-25 | — | — | EP | disclosed |
| CN-111868049-A | Methods of making somatostatin modulators | 克林提克斯医药股份有限公司 | 2020-10-30 | — | — | CN | disclosed |
| US-20200048219-A1 | PROCESS OF MAKING SOMATOSTATIN MODULATORS | Crinetics Pharmaceuticals, Inc. | 2020-02-13 | — | — | US | disclosed |
| US-10464918-B2 | Process of making somatostatin modulators | Crinetics Pharmaceuticals, Inc. (US) | 2019-11-05 | — | — | US | disclosed |
| WO-2019143718-A1 | PROCESS OF MAKING SOMATOSTATIN MODULATORS | Crinetics Pharmaceuticals, Inc. (US) | 2019-07-25 | — | — | WO | disclosed |
| US-20190218202-A1 | PROCESS OF MAKING SOMATOSTATIN MODULATORS | Crinetics Pharmaceuticals, Inc. | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10464918-B2 | Process of making somatostatin modulators | SSTR5, SSTR4, SSTR2 | EGFR 1879/4885ERBB2 2343/4885DYRK1A 2915/4885 |
| US-20190218202-A1 | PROCESS OF MAKING SOMATOSTATIN MODULATORS | SSTR5, SSTR4, SSTR2 | EGFR 1879/4885ERBB2 2343/4885DYRK1A 2915/4885 |
| US-20240376067-A1 | PROCESS OF MAKING SOMATOSTATIN MODULATORS | SSTR5, SSTR4, SSTR2 | EGFR 1879/4885ERBB2 2343/4885DYRK1A 2915/4885 |
| US-20210087165-A1 | PROCESS OF MAKING SOMATOSTATIN MODULATORS | SSTR5, SSTR4, SSTR2 | EGFR 1879/4885ERBB2 2343/4885DYRK1A 2915/4885 |
| US-20200048219-A1 | PROCESS OF MAKING SOMATOSTATIN MODULATORS | SSTR5, SSTR4, SSTR2 | EGFR 1879/4885ERBB2 2343/4885DYRK1A 2915/4885 |
| US-10889561-B2 | Process of making somatostatin modulators | SSTR5, SSTR4, SSTR2 | EGFR 1879/4885ERBB2 2343/4885DYRK1A 2915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.